Bristol-Myers Squibb is expected to report Q2 2026 revenue of $11.67 billion and an adjusted EPS of $1.59, with the current stock price of $62.54 trading just below the average analyst target of $62.96.
Investors are laser-focused on the performance of the company's New Product Portfolio, which is critical for offsetting the rapid revenue decline of the legacy blockbuster Revlimid.
Key drivers under scrutiny include the commercial uptake of the subcutaneous formulation Opdivo Qvantig and sales growth for newer products like Camzyos and Reblozyl.
Management's ability to maintain its full-year 2026 EPS guidance of $6.05 to $6.35 remains a vital factor for sentiment as the company navigates a major patent cliff late this decade.